Ascot rebrands under new management, lays out hub-and-spoke plan
The new management views the Red Mountain project as a key part of the company's new vision.
Amplia Therapeutics CEO outlines 2023 milestones
(via NewsDirect)
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his move into the leadership role late last year. Amplia is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Copyright (c) 2023 TheNewswire - All rights reserved.
